title: Bilateral Synchronous Sporadic Renal Cell Carcinoma: Retroperitoneoscopic Strategies and Intermediate Outcomes of 60 Patients.
abstract: To evaluate the presentation, management, pathology, and functional and oncological outcomes of patients undergoing retroperitoneoscopic treatment of bilateral synchronous sporadic RCC at our institution.
  
  
  
  We retrospectively evaluated the records of 60 patients with bilateral synchronous sporadic RCC who underwent retroperitoneoscopic treatment at the General Hospital of People's Liberation Army from 2008 to 2014. The estimated glomerular filtration rate was calculated and compared among different surgical procedures. The overall survival and recurrence free survival were assessed based on information from recent follow-up.
  
  
  
  Fifty-six patients underwent bilateral retroperitoneoscopic surgeries in staged procedures, and four patients underwent bilateral retroperitoneoscopic surgeries in simultaneous procedures. Among the former group of patients, 34 underwent bilateral partial nephrectomy, 12 underwent radical nephrectomy followed by partial nephrectomy, and 10 underwent partial nephrectomy followed by radical nephrectomy. Bilateral partial nephrectomy can better preserve renal function (p = 0.040) and the sequence of partial nephrectomy and radical nephrectomy did not affect functional outcomes (p = 0.790). One patient undergoing simultaneous procedures developed acute renal failure and required temporary hemodialysis. At 3 and 5 years, overall survival rates were 93.0% and 89.4%, and recurrence free survival rates were 90.5% and 81.6%. High nuclear grade (p = 0.014) was related to disease recurrence.
  
  
  
  Staged bilateral partial nephrectomy was efficient in preserving renal function. The survival of patients with bilateral synchronous sporadic renal tumors was similar to that of patients with unilateral nonmetastatic tumors. Nuclear grade was an independent prognostic factor of disease recurrence.
authors.affiliation: Department of Urology, Chinese PLA General Hospital/Chinese PLA Medical Academy, Beijing, P. R. China.
authors.forename: Baojun
authors.initials: B
authors.lastname: Wang
authors.affiliation: Department of Urology, Chinese PLA General Hospital/Chinese PLA Medical Academy, Beijing, P. R. China.
authors.forename: Huijie
authors.initials: H
authors.lastname: Gong
authors.affiliation: Department of Urology, Chinese PLA General Hospital/Chinese PLA Medical Academy, Beijing, P. R. China.
authors.forename: Xu
authors.identifier: 0000-0002-0608-6509
authors.initials: X
authors.lastname: Zhang
authors.affiliation: Department of Urology, Chinese PLA General Hospital/Chinese PLA Medical Academy, Beijing, P. R. China.
authors.forename: Hongzhao
authors.initials: H
authors.lastname: Li
authors.affiliation: Department of Urology, Chinese PLA General Hospital/Chinese PLA Medical Academy, Beijing, P. R. China.
authors.forename: Xin
authors.initials: X
authors.lastname: Ma
authors.affiliation: Department of Urology, Chinese PLA General Hospital/Chinese PLA Medical Academy, Beijing, P. R. China.
authors.forename: Erlin
authors.initials: E
authors.lastname: Song
authors.affiliation: Department of Urology, Chinese PLA General Hospital/Chinese PLA Medical Academy, Beijing, P. R. China.
authors.forename: Jiangping
authors.initials: J
authors.lastname: Gao
authors.affiliation: Department of Urology, Chinese PLA General Hospital/Chinese PLA Medical Academy, Beijing, P. R. China.
authors.forename: Jun
authors.initials: J
authors.lastname: Dong
mesh_terms: D000328:Adult; D000368:Aged; D002292:Carcinoma, Renal Cell / Q000401:mortality / Q000601:surgery* / Q000628:therapy; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007668:Kidney / Q000473:pathology / Q000601:surgery; D007680:Kidney Neoplasms / Q000401:mortality / Q000601:surgery* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000401:mortality / Q000601:surgery / Q000628:therapy; D009367:Neoplasm Staging; D009392:Nephrectomy; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome